JPWO2022046651A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022046651A5 JPWO2022046651A5 JP2023513103A JP2023513103A JPWO2022046651A5 JP WO2022046651 A5 JPWO2022046651 A5 JP WO2022046651A5 JP 2023513103 A JP2023513103 A JP 2023513103A JP 2023513103 A JP2023513103 A JP 2023513103A JP WO2022046651 A5 JPWO2022046651 A5 JP WO2022046651A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- formulation
- buffer
- antibody construct
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069432P | 2020-08-24 | 2020-08-24 | |
| US63/069,432 | 2020-08-24 | ||
| US202163197020P | 2021-06-04 | 2021-06-04 | |
| US63/197,020 | 2021-06-04 | ||
| PCT/US2021/047181 WO2022046651A1 (en) | 2020-08-24 | 2021-08-23 | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538669A JP2023538669A (ja) | 2023-09-08 |
| JPWO2022046651A5 true JPWO2022046651A5 (https=) | 2024-08-30 |
| JP2023538669A5 JP2023538669A5 (https=) | 2024-08-30 |
Family
ID=78000768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513103A Pending JP2023538669A (ja) | 2020-08-24 | 2021-08-23 | Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230348596A1 (https=) |
| EP (1) | EP4200333A1 (https=) |
| JP (1) | JP2023538669A (https=) |
| KR (1) | KR20230058432A (https=) |
| AU (1) | AU2021330845A1 (https=) |
| BR (1) | BR112023002923A2 (https=) |
| CA (1) | CA3185960A1 (https=) |
| CL (1) | CL2023000486A1 (https=) |
| IL (1) | IL299242A (https=) |
| MX (1) | MX2023002280A (https=) |
| WO (1) | WO2022046651A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022256359A1 (en) * | 2021-06-01 | 2022-12-08 | Amgen Inc. | Accelerated method of making lyophilized protein formualtions |
| US20260083841A1 (en) * | 2022-09-14 | 2026-03-26 | Amgen Inc. | Bispecific Molecule Stabilizing Composition |
| WO2025080688A1 (en) | 2023-10-12 | 2025-04-17 | Amgen Inc. | Compositions of bispecific antibody constructs to human dll3 and human cd3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| TN2019000225A1 (en) * | 2017-02-02 | 2021-01-07 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
| MX2019013142A (es) * | 2017-05-05 | 2019-12-16 | Amgen Inc | Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion. |
| CN110869050B (zh) * | 2017-07-28 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 双特异性抗体配制剂 |
| UY38080A (es) * | 2018-02-08 | 2019-08-30 | Amgen Inc | FORMULACIÓN FARMACÉUTICA DE pH BAJO |
| BR112021004649A2 (pt) * | 2018-09-13 | 2021-06-01 | F. Hoffmann-La Roche Ag | formulação farmacêutica e uso de uma formulação |
| MX2021003628A (es) * | 2018-10-01 | 2021-05-27 | Amgen Inc | Metodos para reducir la agregacion de anticuerpos biespecificos. |
-
2021
- 2021-08-23 AU AU2021330845A patent/AU2021330845A1/en active Pending
- 2021-08-23 US US18/022,685 patent/US20230348596A1/en active Pending
- 2021-08-23 BR BR112023002923A patent/BR112023002923A2/pt unknown
- 2021-08-23 WO PCT/US2021/047181 patent/WO2022046651A1/en not_active Ceased
- 2021-08-23 CA CA3185960A patent/CA3185960A1/en active Pending
- 2021-08-23 MX MX2023002280A patent/MX2023002280A/es unknown
- 2021-08-23 EP EP21783077.7A patent/EP4200333A1/en active Pending
- 2021-08-23 IL IL299242A patent/IL299242A/en unknown
- 2021-08-23 KR KR1020237009363A patent/KR20230058432A/ko active Pending
- 2021-08-23 JP JP2023513103A patent/JP2023538669A/ja active Pending
-
2023
- 2023-02-17 CL CL2023000486A patent/CL2023000486A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11286294B2 (en) | Anti-RSV monoclonal antibody formulation | |
| US20250163142A1 (en) | Formulations of monoclonal antibodies | |
| EP1409018B1 (en) | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab | |
| EP2892504B1 (fr) | Solution aqueuse de protéine à concentration élevée de viscosité réduite | |
| US12251474B2 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| JP2008520551A5 (https=) | ||
| TW201000128A (en) | Novel formulation | |
| KR20090021298A (ko) | 항-ｅｇｆｒ 항체의 동결건조 제제 | |
| US20090068196A1 (en) | Pharmaceutical formulation of an antibody against IL13Ralpha1 | |
| JP2026048681A (ja) | 安定した抗ｐｄ－１抗体薬剤学的製剤 | |
| JPWO2022046651A5 (https=) | ||
| US20040247588A1 (en) | Formulations of modified antibodies and methods of making the same | |
| JP2025535500A (ja) | 抗ネクチン－４抗体－薬物コンジュゲートを含む調製物及びその使用 | |
| JPWO2022256359A5 (https=) | ||
| JPWO2021222355A5 (https=) | ||
| CN113813377A (zh) | 抗α4β7抗体制剂及其应用 | |
| JPWO2021222347A5 (https=) | ||
| WO2000076480A9 (en) | Pharmaceutical materials and methods for their preparation and use | |
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А | |
| WO2025037188A1 (en) | Pharmaceutical composition of daptomycin. | |
| JP2025514115A (ja) | 凍結乾燥方法 | |
| CA3272019A1 (en) | Preparation containing anti-nectin-4 antibody drug conjugate and use thereof | |
| WO2023140807A1 (en) | Pharmaceutical compositions of trastuzumab | |
| WO2025037189A1 (en) | Daptomycin formulation | |
| JPWO2022271544A5 (https=) |